Conference Coverage
Conference Coverage
‘Best’ for most APL patients: Chemo-free regimen
A chemo-free treatment regimen significantly improves survival over chemotherapy in patients with a rare, virulent leukemia, but those 50 and...
Conference Coverage
CAR-T hikes overall survival in relapsed/refractory LBCL
Investigators say axi-cel should become the standard of care for second-line large B-cell lymphoma.
Conference Coverage
`Remarkable’: CAR T therapy for CLL/SLL
Primary analysis of the TRANSCEND CLL 004 trial showed that a single dose of CAR T therapy achieved durable responses in CLL and SLL, with a...
Conference Coverage
ER+/HER2– breast cancer: Is first or second line CDK4/6 inhibitor therapy better?
New study challenges the need for using CDK4/6 inhibitors as first line treatment, according to author.
Conference Coverage
PMBCL: Postremission, patients may safely skip radiation
Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found...
Conference Coverage
Metronomic chemotherapy performs well in second-line head and neck cancer
Lower-dose therapy granted PFS and OS gains, with fewer side effects, compared with standard chemotherapy options.
Conference Coverage
Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancer
A novel therapy has a favorable safety profile, and more like it may be on the way.
Conference Coverage
Oral drug for brain tumor could change treatment landscape
Vorasidenib was associated with a significant delay in time to disease progression when compared with placebo, in a new study.
Conference Coverage
Up-front pembro plus chemo boost survival in cervical cancer
Adding immunotherapy resulted in a 40% reduction in risk of death, compared with chemotherapy alone, for women with advanced cervical cancers...
Conference Coverage
Ribociclib forestalls recurrence also in early breast cancer
New results come from an interim analysis of a phase 3 randomized trial comparing maintenance therapy with ribociclib plus endocrine therapy with...
